News Digest / Ticker: APVO

Ticker: APVO

09:04am, Monday, Aug 11, 2025

Aptevo extends runway after financings; mipletamig shows 85% remission, going‑concern noted

Snapshot - Aptevo Therapeutics Inc. (NASDAQ: APVO) Bottom line: Aptevo is a small clinical-stage biotech that reported continued operating losses for H1 2025 while extending liquidity through multiple equity financings and a standby facility. Clinical progress (notably mipletamig) and fresh finan...